Is Metagenomi's IPO a Risky Bet in a Cooling Gene-Editing Market?

Metagenomi, an in vivo gene-editing company, has recently filed for an initial public offering (IPO) in the United States under the tick-symbol MGX. As one of the few preclinical gene-editing biotech companies to go public in the past two years, Metagenomi faces a less enthusiastic investment climate for the field.

Founded in 2018 by Brian Thomas and Jillian Banfield, metagenomic scientists at the University of California, Berkeley, Metagenomi has developed a range of modular and diverse toolboxes utilizing metagenomics. Their approach aims to tap into four billion years of microbial evolution to precisely target any locus in the human genome.

Using high-throughput screening, artificial intelligence, and proprietary algorithms, Metagenomi analyzes vast amounts of genomic data to mine novel proteins and create genome editing tools. To date, they have analyzed over 460 trillion base pairs, predicted billions of proteins, and identified millions of CRISPR-associated proteins and CRISPRs.

With $350 million in financing, including a $75 million Series A round in May 2021 and a $100 million Series B+ round in January 2023, Metagenomi has attracted more than 30 investors, including Bayer, RACapital, Moderna, Novo Nordisk's venture capital arm, BMS, SymBiosis, and Catalio Capital Management.

Despite these achievements, Metagenomi has not yet advanced a drug to the clinical stage. However, they have established partnerships with prominent biotech companies like Moderna and Ionis. In collaborations with Moderna and Ionis, Metagenomi aims to develop genetic disease treatment programs and a next-generation gene-editing system for multiple targets.

While Metagenomi's collaborations hold promise, the gene-editing therapy sector is currently experiencing a downturn. Companies like Intellia Therapeutics and Aera Therapeutics have recently announced layoffs, reflecting the challenging market conditions. It remains uncertain whether Metagenomi, without a clinical pipeline, will receive strong support from the capital market.

As of September 30, 2023, Metagenomi reported a net loss of $48.96 million with cooperative recognition revenue of $32.35 million and R&D support of $69.64 million. They had $101 million in cash and equivalents and $191 million in marketable securities.

Investing in Metagenomi's IPO carries inherent risks, given the cooling gene-editing market and the lack of a clinical pipeline. However, the company's partnerships with industry leaders and their innovative approach based on metagenomics could attract investors looking for long-term potential in the gene-editing field.